A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single- Ascending Doses of MEDI6012 in Subjects With Stable Coronary Artery Disease
Phase of Trial: Phase II
Latest Information Update: 20 Jan 2017
At a glance
- Drugs MEDI 6012 (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions; Pharmacodynamics
- Sponsors MedImmune
- 17 Jan 2017 Status changed from active, no longer recruiting to completed.
- 11 Nov 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2016.
- 11 Nov 2016 Status changed from recruiting to active, no longer recruiting.